Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)
Phase 3
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Advanced Non-Small Cell Lung Cancer
Both
Advanced Non-Small Cell Lung Cancer
Trial Information
Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)
Inclusion Criteria:
- Non-small cell lung cancer stage IIIB or IV
- Not eligible for radical radiotherapy or surgery
- WHO performance status 0-2
Exclusion Criteria:
- Pregnancy
- Other clinical active cancer disease
- ALAT/ALP more than 3 times upper normal limit, bilirubin >1.5 upper limit
- Bowel disease that causes malabsorption
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
survival
Outcome Time Frame:
one year
Safety Issue:
No
Principal Investigator
Øystein Fløtten
Investigator Role:
Study Chair
Investigator Affiliation:
Haukeland University Hospital, thoracic department
Authority:
Norway: Norwegian Medicines Agency
Study ID:
11066741577
NCT ID:
NCT00737867
Start Date:
September 2007
Completion Date:
February 2011
Related Keywords:
- Advanced Non-Small Cell Lung Cancer
- lung cancer
- chemotherapy
- vinorelbine
- gemcitabine
- carboplatin
- advanced lung cancer
- non-small cell lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
